Anti-CCNT1 Intrabody [Tat] (IAB-B032(T))
Recombinant anti-CCNT1 intrabody in fusion with HIV Tat works within cells to bind human CCNT1, expressed in 293T cells. Anti-hCyclinT1 intrabodies can be designed to block HIV-1 replication without causing cellular toxicity, and as a result, they may be useful agents for "intracellular immunization"-based gene therapy strategies for HIV-1 infection/AIDS.
Specifications
- Immunogen
- human cyclin T1
- Host
- human
- Type
- scFv-Tat
- Cell Penetrating Peptide
- TAT
TAT was able to deliver different proteins, such as horseradish peroxidase and RNase A across cell membrane into the cytoplasm in different cell lines in vitro. The size range of proteins with effective delivery is from 30kDa to 120-150kDa. In one study, TAT-fused proteins are rapidly internalized by lipid raft−dependent macropinocytosis using a transducible TAT−Cre recombinase reporter assay on live cells. In another study, a TAT-fused protein was delivered into mitochondria of breast cancer cells and decreased the survival of breast cancer cells, which showed capability of TAT-fusion proteins to modulate mitochondrial function and cell survival. However, very few in vivo studies have succeeded. In one study, in vivo delivery of TAT- or penetratin-crosslinked Fab fragments yielded varied organ distributions and an overall increase in organ retention, which showed tissue localization.
- Species Reactivity
- human
- Applications
- Can be useful in applications such as: Enzyme-linked Immunosorbent Assay; Immunocytochemistry; Functional studies
Target
- Alternative Names
- CCNT1; cyclin T1; CCNT; CYCT1; HIVE1; cyclin-T1; cyclin C-related protein; CDK9-associated C-type protein
- Entrez Gene ID
- 904
- UniProt ID
- O60563
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: